Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies

European Journal of Cardio-thoracic Surgery

Volumn 37, Issue 6, 2010, Pages 1375-1383

  Ngaage, Dumbor L ^a   Bland, John Martin ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cardiac surgery; Risk (morbidity, mortality); Tranexamic acid

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; PLACEBO; TRANEXAMIC ACID;

BLEEDING; BLOOD CONSERVATION; CARDIAC PATIENT; CLINICAL TRIAL; COCHRANE LIBRARY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; HEART SURGERY; HUMAN; INFORMATION RETRIEVAL; LOADING DRUG DOSE; MEDLINE; META ANALYSIS; NEUROLOGICAL COMPLICATION; OBSERVATIONAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REOPERATION; REVIEW; SINGLE DRUG DOSE; SURGICAL MORTALITY;

ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANEXAMIC ACID;

EID: 77952582367     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.11.055     Document Type: Review

References (46)

1. Fergusson D.A., Hebert P.C., Mazer C.D., Fremes S., MacAdams C., Murkin J.M., Teoh K., Duke P.C., Arellano R., Blajchman M.A., Bussieres J.S., Cote D., Karski J., Martineau R., Robblee J.A., Rodger M., Wells G., Clinch J., and Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 22 (2008) 2319-2331
2. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 4 (2006) 353-365
3. Schneeweiss S., Seeger J.D., Landon J., and Walker A.M. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358 8 (2008) 771-783
4. Shaw A.D., Stafford-Smith M., White W.D., Phillips-Bute B., Swaminathan M., Milano C., Welsby I.J., Aronson S., Mathew J.P., Peterson E.D., and Newman M.F. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 8 (2008) 784-793
5. Ngaage D.L., Cale A.R., Cowen M.E., Griffin S., and Guvendik L. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann Thorac Surg 86 4 (2008) 1195-1202
6. Pagano D., Howell N.J., Freemantle N., Cunningham D., Bonser R.S., Graham T.R., Mascaro J., Rooney S.J., Wilson I.C., Cramb R., and Keogh B.E. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 135 3 (2008) 495-502
7. Royston D. Aprotinin; an economy of truth?. J Thorac Cardiovasc Surg 136 3 (2008) 798-799 author reply 799
8. Sundt T.M. The demise of aprotinin: our share of the blame. J Thorac Cardiovasc Surg 135 4 (2008) 729-731
9. Westaby S. Aprotinin: twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg 135 3 (2008) 487-491
10. Breuer T., Martin K., Wilhelm M., Wiesner G., Schreiber C., Hess J., Lange R., and Tassani P. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg 35 1 (2009) 167-171 author reply 171
11. de Leede-van der Maarl M.G., Hilkens P., and Bosch F. The epileptogenic effect of tranexamic acid. J Neurol 246 9 (1999) 843
12. Hui A.C., Wong T.Y., Chow K.M., and Szeto C.C. Multifocal myoclonus secondary to tranexamic acid. J Neurol Neurosurg Psychiatry 74 4 (2003) 547
13. Martin K., Wiesner G., Breuer T., Lange R., and Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 107 6 (2008) 1783-1790
14. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 9193 (1999) 1896-1900
15. Hozo S.P., Djulbegovic B., and Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5 1 (2005) 13
16. Fawzy H., Elmistekawy E., Bonneau D., Latter D., and Errett L. Can local application of tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. J Cardiothorac Surg 4 (2009) 25
17. Mengistu A.M., Rohm K.D., Boldt J., Mayer J., Suttner S.W., and Piper S.N. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery. Anesth Analg 107 2 (2008) 391-397
18. Lindvall G., Sartipy U., Ivert T., and van der Linden J. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann Thorac Surg 86 1 (2008) 13-19
19. Dietrich W., Spannagl M., Boehm J., Hauner K., Braun S., Schuster T., and Busley R. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Anesth Analg 107 5 (2008) 1469-1478
20. Baric D., Biocina B., Unic D., Sutlic Z., Rudez I., Vrca V.B., Brkic K., and Ivkovic M. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg 31 3 (2007) 366-371 discussion 371
21. Santos A.T., Kalil R.A., Bauemann C., Pereira J.B., and Nesralla I.A. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Braz J Med Biol Res 39 1 (2006) 63-69
22. Karkouti K., Beattie W.S., Dattilo K.M., McCluskey S.A., Ghannam M., Hamdy A., Wijeysundera D.N., Fedorko L., and Yau T.M. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 3 (2006) 327-338
23. Abul-Azm A., and Abdullah K.M. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol 23 5 (2006) 380-384
24. Vanek T., Jares M., Fajt R., Straka Z., Jirasek K., Kolesar M., Brucek P., and Maly M. Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur J Cardiothorac Surg 28 4 (2005) 563-568
25. Karski J., Djaiani G., Carroll J., Iwanochko M., Seneviratne P., Liu P., Kucharczyk W., Fedorko L., David T., and Cheng D. Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial. J Thorac Cardiovasc Surg 130 2 (2005) 309-314
26. Diprose P., Herbertson M.J., O'Shaughnessy D., Deakin C.D., and Gill R.S. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth 94 3 (2005) 271-278
27. Armellin G., Vinciguerra A., Bonato R., Pittarello D., and Giron G.P. Tranexamic acid in primary CABG surgery: high vs. low dose. Minerva Anestesiol 70 3 (2004) 97-107
28. Andreasen J.J., and Nielsen C. Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass. Eur J Cardiothorac Surg 26 2 (2004) 311-317
29. Pleym H., Stenseth R., Wahba A., Bjella L., Karevold A., and Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg 96 4 (2003) 923-928 table of contents
30. Zabeeda D., Medalion B., Sverdlov M., Ezra S., Schachner A., Ezri T., and Cohen A.J. Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization. Ann Thorac Surg 74 3 (2002) 733-738
31. Wong B.I., McLean R.F., Fremes S.E., Deemar K.A., Harrington E.M., Christakis G.T., and Goldman B.S. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg 69 3 (2000) 808-816
32. Nuttall G.A., Oliver W.C., Ereth M.H., Santrach P.J., Bryant S.C., Orszulak T.A., and Schaff H.V. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 92 3 (2000) 674-682
33. De Bonis M., Cavaliere F., Alessandrini F., Lapenna E., Santarelli F., Moscato U., Schiavello R., and Possati G.F. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg 119 3 (2000) 575-580
34. Casati V., Guzzon D., Oppizzi M., Bellotti F., Franco A., Gerli C., Cossolini M., Torri G., Calori G., Benussi S., and Alfieri O. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 120 3 (2000) 520-527
35. Mongan P.D., Brown R.S., and Thwaites B.K. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg 87 2 (1998) 258-265
36. Hardy J.F., Belisle S., Dupont C., Harel F., Robitaille D., Roy M., and Gagnon L. Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization. Ann Thorac Surg 65 2 (1998) 371-376
37. Brown R.S., Thwaites B.K., and Mongan P.D. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. Anesth Analg 85 5 (1997) 963-970
38. Katsaros D., Petricevic M., Snow N.J., Woodhall D.D., and Van Bergen R. Tranexamic acid reduces post-bypass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 61 4 (1996) 1131-1135
39. Speekenbrink R.G., Vonk A.B., Wildevuur C.R., and Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 59 2 (1995) 438-442
40. Penta de Peppo A., Pierri M.D., Scafuri A., De Paulis R., Colantuono G., Caprara E., Tomai F., and Chiariello L. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J 22 3 (1995) 231-236
41. Karski J.M., Teasdale S.J., Norman P., Carroll J., VanKessel K., Wong P., and Glynn M.F. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. J Thorac Cardiovasc Surg 110 3 (1995) 835-842
42. Fiechtner B.K., Nuttall G.A., Johnson M.E., Dong Y., Sujirattanawimol N., Oliver Jr. W.C., Sarpal R.S., Oyen L.J., and Ereth M.H. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 92 5 (2001) 1131-1136
43. Lambert W., Brisebois F.J., Wharton T.J., Carrier R.C., Boyle D., and Rowe B.H. The effectiveness of low dose tranexamic acid in primary cardiac surgery. Can J Anaesth 45 6 (1998) 571-574
44. Brown J.R., Birkmeyer N.J., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 22 (2007) 2801-2813
45. Henry D., Carless P., Fergusson D., and Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 180 2 (2009) 183-193
46. Takagi H., Manabe H., Kawai N., Goto S.N., and Umemoto T. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials. Interact Cardiovasc Thorac Surg 9 1 (2009) 98-101